|

MK-3475 Clinical Trials

2 actively recruiting trials

Also known as: Keytruda/MK-3475 (Pembrolizumab), Pembrolizumab

Pipeline

Phase 2: 2

Top Sponsors

  • National Cancer Center, Japan1
  • Kyoto University Hospital1

Indications

  • Cancer2
  • Untreated Advanced or Recurrent Thymic Carcinomas1
  • Bladder Cancer1

Other2 trials

First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Phase 2
Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.